The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer
Official Title: Shandong Provincial Hospital Affiliated to Shandong University
Study ID: NCT04102982
Brief Summary: Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
Detailed Description: Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days. The primary end point is overall survival. The second end points include progression free survival, objective response rate and safety.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Binzhou Medical University Hospital, Binzhou, Shandong, China
Dezhou People's Hospital, Dezhou, Shandong, China
The Second People's Hospital of Dezhou, Dezhou, Shandong, China
Jinan Military General Hospital, Jinan, Shandong, China
Affliated Hospital of Shandong Academy of Medical Sciences, Jinan, Shandong, China
Shandong Provincial Hospital affliated to Shandong University, Jinan, Shandong, China
Affliated Hospital of Jining Medical University, Jining, Shandong, China
Liaocheng Cancer Hospital, Liaocheng, Shandong, China
Affliated Hospital of Taishan Medical University, Taian, Shandong, China
The People's Liberation Army 88 Hospital, Taian, Shandong, China
Weifang People's Hospital, Weifang, Shandong, China
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Tengzhou center of people's hospital, Zaozhuang, Shandong, China
Name: Xin Ye
Affiliation: Shandong Provincial Hospital
Role: PRINCIPAL_INVESTIGATOR